KIT D816V ESC 1
ESIBIe003-A-8
General
Cell Line |
|
| hPSCreg name | ESIBIe003-A-8 |
| Cite as: | ESIBIe003-A-8 |
| Alternative name(s) |
KIT D816V ESC 1
|
| Cell line type | Human embryonic stem cell (hESC) |
| Similar lines |
ESIBIe003-A-9 (KIT D816V ESC 2) ESIBIe003-A (HES-3, hES 3) ESIBIe003-A-4 (Envy) ESIBIe003-A-3 (hES3.3) ESIBIe003-A-7 (HES-3_44, IRF8-/- ES cell) ESIBIe003-A-1 (hES3.1) ESIBIe003-A-2 (hES3.2) ESIBIe003-A-11 (KIT+/- ESC) ESIBIe003-A-12 (KIT-/- ESC) |
| Last update | 11th March 2021 |
| User feedback | |
Provider |
|
| Generator |
Universitätsklinikum Aachen (UKA)
Contact:
Universitätsklinikum Aachen (UKA) |
| Owner | Universitätsklinikum Aachen (UKA) |
| Distributors | |
| Derivation country | Germany |
External Databases |
|
| BioSamples | SAMEA8359801 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA104620499 |
Ethics
Also have a look at the ethics information for the parental line
ESIBIe003-A
.
| Is there an MTA available for the cell line? | Yes |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hESC Derivation
|
The source cell information can be found in the parental cell line
ESIBIe003-A.
|
Culture Conditions
| Surface coating | Gelatin | |||||||||||||||||||||
| Feeder cells |
mouse embryonic fibroblast |
|||||||||||||||||||||
| Passage method |
Enzymatically
Collagenase
|
|||||||||||||||||||||
| O2 Concentration | 21 % | |||||||||||||||||||||
| CO2 Concentration | 5 % | |||||||||||||||||||||
| Medium |
Other medium:
Base medium: Knock out DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.